Unraveling the IGF System Interactome in Sarcomas Exploits Novel Therapeutic Options.

ABSTRACT: Aberrant bioactivity of the insulin-like growth factor (IGF) system results in the development and progression of several pathologic conditions including cancer. Preclinical studies have shown promising anti-cancer therapeutic potentials for anti-IGF targeted therapies. However, a clear but limited clinical benefit was observed only in a minority of patients with sarcomas. The molecular complexity of the IGF system, which comprises multiple regulators and interactions with other cancer-related pathways, poses a major limitation in the use of anti-IGF agents and supports the need of combinatorial therapeutic strategies to better tackle this axis. In this review, we will initially highlight multiple mechanisms underlying IGF dysregulation in cancer and then focus on the impact of the IGF sys

SUBMITTER: Mancarella C 

PROVIDER: S-EPMC8392407 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature